Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
Phase 2Small molecule
Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP) is one of 8 small molecule programs targeting Olfactory Neuroblastoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Olfactory Neuroblastoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonApproved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Vepesid
AAvyxa
Approved
Opdivo
Bristol-Myers SquibbPhase 2
Advil
KKenvue Brands
Phase 2
Rivoceranib
EElevar Therapeutics
Phase 2
Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
HHongmeng Yu
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHongmeng Yu